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ABSTRACT
Kava, prepared as the traditional aqueous infusion, was tested in the rat for possible
effects on liver function tests. Extracts were administered in dosages containing 200 or
500 mg of the active kavalactones per kg for two or four weeks. Sera were assayed for
four enzymes that are markers of liver toxicity and liver homogenates for
malondiadehyde formation that indicates changes in lipid peroxidation. The data showed
that none of the enzymes, alanine aminotransferase, aspartate aminotransferase, alkaline
phosphatase, and lactate dehydrogenase, nor malondialdehyde levels were elevated, in
fact in some cases they were significantly reduced, suggesting the lack of a toxic effect
on the liver by kava.
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INTRODUCTION
Kava (Piper methysticum Forst f., family Piperaceae) is an herb that has been used
for ceremonials and rituals by inhabitants of the South Pacific (Singh, 1992; Lebot et al.,
1997). It is now sold widely in western countries as an herbal supplement to treat stress,
anxiety, insomnia and restlessness (Singh and Singh, 2002). Until recently, it was reputed
to cause no severe toxicity apart from a skin condition called kava dermopathy which
occurs on prolonged and excessive use. However, in the past few years, about 35 cases of
hepatotoxicity apparently associated with kava use have been reported from Europe,
mostly in Germany and Switzerland, with some additional cases from the United States
(MMWR, 2002; Schmidt, 2002; Waller, 2002). The adverse event reports (AERs) for
these incidents included cholestatic hepatitis, jaundice, increased Uver enzymes, Uver cell
impairment, severe hepatitis with confluent necrosis and irreversible liver damage; in a
few cases, liver transplantation became necessary. Although much of the data on most of
the cases were either incomplete or generally xmavailable, relatively detailed information
has been published for five of them (Singh and Singh, 2002). The AERs have prompted a
number of countries to take regulatory action to either suspend the sale of kava products
or issue health advisories on their use.
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These incidents of hepatotoxicity are somewhat surprising in light of the experience
of South Pacific islanders who have safely consumed kava for many centuries. In those
communities, only men consume kava, often habitually and in much larger amounts than
used in the west, yet their incidence of liver toxicity is low and similar to that of island
women who do not take kava. Fiuthermore, the commercial products were manufactured
using organic solvents that are confirmed hepatotoxins, such as acetone, ethanol, or
chloroform, in contrast to the water infusions drunk by the islanders. Whether the
extraction procedme introduces some toxic plant components or solvent residue into the
final product has not been established (Singh and Singh, 2002).
A number of independent reviews of the reported cases have been done and are
revealing. In one analysis of a total listing of 35 AERs from Germany (Schmidt and
Nahrstedt, 2002), four were double or triple listed, in four cases had no association with
kava, causal relationship with comedications was probable for 14 cases, doubtfiil but not
definitely excluded in four others, not assessable in six cases, and in three others causal
relationship with kava was probably due to abuse or excessive intake. Thus only in the
one remaining incident was there probable causal relationship in dosages conforming to
the German Commission E monograph (Blumenthal et al., 1998). The authors also note
that in a majority of the German cases the documentation was "far fi-om complying with
the current requirements of the relevant European guidelines" for AER reporting and that
"the allocation of kava [to hepatotoxicity] is not logical in the majority of cases and
appears arbitrary. Furthermore, in many cases, available information is not taken into
account, e.g., with regard to other causes." An extreme example they cite is the one
fatality where "it was evidently known ... that the cause of liver failure was due to many
years of alcohol abuse and that kava was not involved in the development of liver
symptoms - the biopsy showed that cirrhotic processes in the liver had started long
before kava was taken!"

Based on another analysis of 30 AERs from Germany and five submitted to the
FDA, it was concluded that there is "no clear evidence that the liver damage reported in
the U.S. and Europe was caused by the consumption of kava," and that those cases in
which there is a possible association between the use of a kava extract and liver
dysfunction" appear to have been hypersensitivity or idiosyncratic base responses"
(Waller, 2002).

The possibility of an interaction between kavalactones and pharmaceutical drugs
resulting in hepatotoxicity has recently received some attention. A major way in which
such interaction may occur is by an inhibition of cytochrome P450 (CYP 450) enzymes
by kavalactones. Since these enzymes are responsible for the hepatic metabolism of a
majority of drugs and xenobiotics, their inhibition could elevate the plasma
concentrations of these drugs to toxic levels.
In a study of the actions of the six major kavalactones on cDNA-derived CYP450
enzymes, the most potent inhibition of CYPl A2 occiured with desmethoxyyangonin
(DMY); of CYP2C19 with dihydromethysticin (DHM), DMY, and methysticin (M); and
of CYP3A4 with DHM and M (Zou et al., 2002). The inhibition of CYP450 enzymes by
whole kava extract and individual kavalactones was also investigated in human liver
microsomes (Mathews et al., 2002). The extract caused significant inhibition of the
activities of CYP1A2,2C9, 2C19, 2D6, and 3A4 while CYP2A6,2C8, and 2E1 activities
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were unaffected. While kavain did not inhibit CYP2C9, 2C19,2D6, and 3A4, there was

significant inhibition of CYP2C9 by M, DHM, and DMY; of 2C19 by DHM; of 2D6 by
M; and of 3A4 by DMY, DHM, and M. These data indicate that kava has a high potential
for causing drug interactions through inhibition of CYP450 enzymes responsible for the
metabohsm of a large number of medications.
Genetic polymorphism of many GYP enzymes, leading to interindividual variation
in drug metabolism, may be another factor in the marked discrepancy in hepatotoxic
response to kava of Pacific Islanders on the one hand and Caucasians on the other. The
enzyme CYP2D6 is thought to cause much of the interindividual variations seen in drug
responses, adverse effects, and interactions with drugs (Poolsup et aL, 2002). Individuals
may be poor (slow), intermediate, extensive (fast), or ultrafast metabolizers. In a
Caucasian population 7-9% of individuals are homozygous deficient in CYP2D6 and
thus are poor metabolizers (Poolsup et al., 2002). On the other hand, the incidence of
CYP2D6 deficiency is almost 0% in persons of pure Polynesian descent (Wanwimolruk
et al., 1998). Since this enzyme is a major metabolizer of kavalactones, it is tempting to
speculate that the genetic variability between Caucasian kava users and the Pacific
Islanders may be a major contributory factor. However, the genetic polymorphism of
CYP2D6 for Melanesians of Fiji, Vanuatu, and other kava consuming nations or that of
other CYP enzymes in the Pacific island populations is yet to be determined.
The purpose of this research was to evaluate the level of toxicity induced by kava
administration on hver function in yoimg Sprague-Dawley rats by measuring its effects
on several enzymes that are markers for liver toxicity, and formation of malondialdehyde,
a byproduct of lipid peroxidation that may result in liver damage. A significant increase
in these enzymes or malondialdehyde is considered an indication of liver toxicity. Rats
were treated for two or four weeks, with a placebo or an aqueous infusion of kava in
dosages of 200 or 500 mg kavalactones per kg per day. The results showed that there was
no significant difference in the activity of the four serum enzymes, or the amount of
malondialdehyde formed at either of the two doses, or at each of the two time points
compared to the control groups. We believe the work presented provides good indication
that kava prepared in the traditional manner and in kavalactones levels up to three times
that recommended by Commission E shows no significant indication of liver dysfunction
in rats.

MATERIALS AND METHODS
Kava extract preparation
Dried kava root was obtained directly from Fiji where it was collected and
authenticated at the South Pacific Herbarium, Suva. A voucher specimen has been stored
in Herbariiun. Eight grams of the powdered kava was extracted in 50 ml of water by
sonication for 20 min at room temperature (-21 ± 1° F) and then centrifiiged at 10,000xg
for 20 min. The supernatant was removed and the residue was re-extracted with 25 ml of
water. The two supematants were combined, the filtrate frozen and then lyophilized. The

dry extract with the natural proportions of the kavalactones was used to make the
appropriate doses for rat administration based on the HPLC assay of their kavalactone

46

AQUEOUS KAVA EXTRACTS

composition. For the purposes of reproducibility, the samebatchof the kavasamplewas
used for the entire study.

HPLC
,
The kavalactone contentof the powderedextract was assayedby a modification of a

previously published andauthenticated reversed phase HPLC method (Ganzera and
Khan, 1999).A Luna C8 column, 100 x 4.6 mm, 3 _m particle size, with a guard colunm
(from Phenomenex,Torrance, CA) was used. The mobile phase was
water:acetonitrile:reagent alcohol (60:25:15v/v). The reagent alcohol consistedof
ethanol 90.7%, methanol 4.6%, and isopropyl alcohol 4.7%. Chromatographicconditions
were: flow rate 0.5 ml/min, detection wavelength 246 nm, injection volume 5 _1,and

running time 25 min.The kavalactone standards, consisting of kavain, dihydrokavain,
methysticin, dihydromethysticin, yangonin, anddesmethoxyyangonin, weredissolved in
acetone. The samples as well as the standards were filteredthrougha 0.22 _m membrane
filter before injection.
Animal Care and Treatment

Sprague-Dawley rats,4 weeks of ageandbodyweight of 225-250 g, wereobtained
from Harlan(Indianapolis, IN). They were randomly divided into six groupsof six
animals each and housed in pairs in a climate-controUed room at 25°C, 12-hour
light/dark cycle, and withfree access to rodentchow (Purina, Richmond, IN) and tap
water. After sevendays of acclimatization, the rats were administered by gavage with
either kava (200 or 500 mg kavalactonesper day) in two divided doses or a saline
placebo. These doses of thekava were about 50%and250%, respectively, higher than
the dose recommendedby the CommissionE monograph. Food and water consumption
as weU as animal body weight were monitoredat the same time of the day every two
days throughout the test period. The care and treatment of the rats werein accordance
withthe guidelines of the PublicHealthService Policyon Humane Care andUse of
Laboratory Animals and were approved by the Institutional AnimalCare and Use
Committee of the University.

Sample collection
After two or four weeks of treatment, the animals were anesthetized with

Phenobarbital (40 mg/kg), the thoraciccavityopenedto exposethe heart, and the blood
drawn by intracardiac puncture. Senimwasprepared and frozen untilusedfor the
enzyme essays. Portions of the liverwereremoved and madeinto homogenates for the
lipid peroxidation experiments.
Enzyme assays

Diagnostic kits from Sigma (St.Louis, MO) wereusedfor the assays of alanine
aminotransferase (ALT), aspartate aminotransferase (AST),alkalinephosphatase (ALP),
and lactatedehydrogenase (LDH) by following the accompanying procedures.
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Lipid peroxidation (LPO)
A modification of the thiobarbutric acid method was employed for the estimation of
malondialdehyde formed (Lee etal., 1991). Briefly, after incubation for 60 min at 37°C,
a 1.0 ml ahquot of the liver homogenate was mixed with 1.0 ml 40% trichloracetic acid
(TCA), followed by addition of 1.0 ml 2% thiobarbutric acid. The mixture was boiled for
15 min, cooled in an ice bath for 5 min, then 1 ml 40% TCA added to it. After standing
for 20 min, the mixture was centrifiiged at 800xg for 20 min, and the absorbance of the
supernatant read at 532 nm. The protein content of the samples was determined by the
Lowry method (Lowry at al, 1951) using a kit from Bio-Rad (Richmond, CA). The
extinction coefficient was used to determine the amount of malondialdehyde
formed/gram protein.

Statistical analysis
Data are means ± S.E.M. of 5-6 replicates. All statistical analyses were performed
using ANOVA followed by Student's t-test, with P<0.05 being regarded as significant.

RESULTS
There were no overt signs of clinical toxicity or behavioral changes in the rats
during either the two or four week treatment period. Compared to the placebo groups,
kava administration did not produce significant (P>0.05) alterations in food or water
intake or in body weight gain (Figure 1).
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Figure 1. Animal bodyweight during the treatment period
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Six majorpeaks whichcorresponded to the six majorkavalactones were obtained
with reversedphase HPLC of the kava infusion.The relative proportionsof the
compounds were as follows: kavain39.45%, dihydrokavain 21.12%, methysticin
24.14%, dihydromethysticin 15.35%, yangonin 11.37%, and desmethoxygangonin 5.7%.
Furthermore, the percentageof total kavalactones in the dried sample was 8.34 ± 0.62
g/100g (n = 4) of the kavastock, whichis in good agreement withliteraturevalues
(Young et al, 1966;Duve, 1981;Lehot and Levesque, 1989).
The serum levels of all four enzymes tested, alanine aminotransferase (ALT),

aspartate aminotransferase (AST), alkaline phosphatase ALP),andlactatedehydrogenase
(LDH), were almost twice as much in the kava-freerats after two weeks comparedto
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Figure 2a. Kavaeffects on alanine transaminase activity after 2 and 4 weeks of treatment
(*+P<0.05)
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Figure 2b. Kava effectson aspartate transaminase activity after2 and 4 weeks of
treatment (*P<0.05)
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four weeks of treatment (Figure 2). After two weeks, all enzymes were lower with both
doses of kava. The change was significant (/'<0.05) at 500 mg/kg kavalactones for ALT
and AST and at 200 mg/kg for ALP. The reduction in ALT was also significant (P<0.05)
after 4 weeks with 500 mg/kg.
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Figure 2c. Kava effects on alkaline phosphatase activity after 2 and 4 weeks of treatment
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Figure 2d. Kava effects on lactate dehydrogenase activity after 2 and 4 weeks of treatment
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The amount of malondialdehyde produced after 4 weeks was significantly greater
(P<0.05) than after 2 weeks for each type of treatment, namely placebo and the two
doses of kava extract. However, at each time point kava did not significantly (P>0.05)
alter the level of lipid peroxidation compared to the corresponding placebo (Figure 3).

Lipid Peroxidation Assay
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Figure 3. Kava effects on lipid peroxidation after 2 and 4 weeks of treatment

DISCUSSION
Aqueous infusions of kava have been used by South Pacific islanders for hundreds
of years without any major adverse effects except for kava dermopathy, a scaly skin
condition, which only occurred on prolonged and excessive intake. Thus it came as a
surprise when cases of hepatotoxicity were associated with kava in reports from Europe
and later, the U.S. Since the herbal supplement is extracted with organic solvents in
contrast to the relatively safe water infusion used by the South Pacific consumers, it
became important to establish whether the aqueous extract manifested any signs or
symptoms of liver dysfunction.
The enzyme assay data clearly indicate that there was no significant increase in any
of the four major marker enzymes for hepatotoxicity. In actuality, there usually were
reductions in the enzyme activities, especially at the lower kava dose. Furthermore, these
changes were significant (P<0.05) in four of the cases, which would suggest that rather
than aqueous kava being hepatotoxic, it might have a hepatoprotective effect, something
that many Pacific islanders have long believed (the faculty mentor is a native of Fiji).
The lipid peroxidation studies were done to determine whether kava constituents
promote any free radical activity that may lead to liver injury. The data show that there
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was no significant increase in the formation of malondialdehyde, indicating the lack of
hepatotoxicity arising from lipid peroxidation.
Although the findings of the present study indicate the absence of a causal
relationship between kavalactones and the apparent kava-induced hepatotoxicity, there
are other considerations that need to be addressed. The doses of kavalactones used were

up to only about three times higher than the recommended maximum whereas toxicity
studies in rodents are normally performed in doses that are up to 10 times larger. It is
also possible that some, but not aU, of the kavalactones cause liver injury and hence the
composition of the extracts in this study and in herbal supplements is highly relevant. In
the present study, kavain and methysticin constituted about 63.6% of the total lactone
content. Chemotypes rich in these two compounds find favor with kava drinkers
apparently because of the desirable psychoactive effects they produce (Lebot and
Levesque, 1989) and also the flavor and taste they impart to the beverage. On the other
hand, chemotypes high in dihydrokavain and dihydromethysticin are shunned as they
appear to lack these properties. These attributes obviously led to a selection by the
islanders of which chemotypes to utilize. The liver toxicity profile of these two
compoimds or of the other four lactones presently is not known; however, should kavain
and methysticin prove to be relatively innocuous in this regard, then this would support
the results of the present study.
The relative proportions of the kavalactones in the commercial products are
established, but wiU probably be different from that in the aqueous infusion because of
their extraction with organic solvents. Whether some or all of the other kavalactones are
hepatotoxic, or larger amoxmts of them or other noxious compounds are extracted
remains to be resolved.
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